Open Access
Access granted
Subscription or Fee Access
No 5 (2013)
- Year: 2013
- Articles: 15
- URL: https://journals.eco-vector.com/2073-4034/issue/view/6807
Articles
10-12
O RATsIONAL'NOM VYBORE FARMAKOTERAPII PRI SAKhARNOM DIABETE 2 TIPA
Abstract
Type 2 diabetes mellitus is a serious, progressive disease that is associated with the development of micro- and macrovascular complications, the prevention of which is an important goal of modern medicine. The pharmacological characteristics, the effectiveness and safety of antidiabetic therapy are discussed. It is emphasized that the use of modern sulfonylureas such as gliclazide, contribute to achieving the main goals of treatment for type 2 diabetes mellitus - maintenance of long-term metabolic control and prevention or delaying the development of vascular complications.
Pharmateca. 2013;(5):13-17
13-17
REGIDRATATsIONNAYa TERAPIYa I VOZMOZhNOSTI EE KONTROLYa U PATsIENTOV S DIABETIChESKIMI KOMAMI (OBZOR LITERATURY)
Abstract
The methods for optimizing the treatment and control of the results of therapy in patients with impaired bodies of water in any diseases, including diabetic coma, are discussed. The impedance spectroscopy allows to simply and reliably control the dynamics of change in water sector of body at early period of the disease, and should be considered as the basis for recommendations for pathogenetically substantiated infusion-transfusion therapy. At the same time, further studies to assess the clinical importance of bioimpedance analysis in diabetic patients with diabetic coma are necessary.
Pharmateca. 2013;(5):18-24
18-24
SOSTOYaNIE KOSTNOY TKANI PRI SAKhARNOM DIABETE 2 TIPA
Abstract
The article considers the influence of many factors associated with type 2 diabetes mellitus (DM2) on bone status (BS). It is emphasized that recent studies have often shown increasing bone mineral density in DM2 patients. At the same time, an increased risk of fractures, both vertebral and proximal femoral neck, in these patients is also practically assured. The latter fact was the determining factor in the categorization of DM2 as a risk factor for osteoporosis. In this connection, wide range of pathogenetical effects on the bone status in DM2 patients has a special importance. Controversial impact of the major characteristics of DM, such as parameters of carbohydrate metabolism, duration of disease, features of influence of glucose-lowering therapy on BS, especially during perimenopause, remains poorly understood and requires further examination of this problem.
Pharmateca. 2013;(5):25-31
25-31
SOVETNIK BOLYuSA": EFFEKTIVNOE I BEZOPASNOE UPRAVLENIE POSTPRANDIAL'NOY GLIKEMIEY U PATsIENTOV NA POMPOVOY INSULINOTERAPII
Abstract
Postprandial blood glucose level is an important «target» for the multifactorial management of diabetes mellitus (DM). However, many patients on insulin do not achieve target postprandial blood glucose levels due to an incorrect calculation of doses. For the facilitation of this task, most of the modern insulin pumps have a predefined function of calculation of prandial insulin dose - “bolus advisor". The present review is devoted to the evaluation of clinical efficacy and safety of such programs.
Pharmateca. 2013;(5):32-36
32-36
INNOVATsIONNAYa SAKhAROSNIZhAYuShchAYa TERAPIYa: NOVAYa STRATEGIYa DLYa STAROY PROBLEMY
Abstract
The paper is devoted to the innovative strategy for the glucose-lowering therapy with using DPP-4 inhibitors. From the position of the evidence medicine the glycemic and non-glycemic effects, the efficacy, safety, the pathogenic aspects and clinical perspectives are wrote by sitagliptin, the first and the most distinguished representative of the incretins.
Pharmateca. 2013;(5):37-47
37-47
SODERZhANIE VITAMINA D 3 I POKAZATELI METABOLIZMA KOSTNOY TKANI U ZhENShchIN S SAKhARNYM DIABETOM 2 TIPA
Abstract
The article presents the results of assessment of levels of vitamin D3, markers of bone metabolism and bone density in women with type 2 diabetes mellitus. It is noted that the decrease in bone mineral density (osteopenia and osteoporosis) is diagnosed in 66 % of patients. Against the background of the acceleration of bone metabolism, the level of vitamin D3 has decreased.
Pharmateca. 2013;(5):48-51
48-51
FARMAKOEKONOMIChESKIY ANALIZ PREIMUShchESTV KOMBINIROVANNOY INKRETINOVOY TERAPII BOL'NYKh SAKhARNYM DIABETOM 2 TIPA NA PRIMERE VILDAGLIPTINA
Abstract
Submitted pharmacoeconomic study included a comparison of the two schemes of use of oral glucose-lowering drugs in patients with type 2 diabetes mellitus: vildagliptin + metformin in the fixed drug combination (Galvus Met 50/1000 mg), and a combination of two drugs - glimepiride (4 mg) and metformin (1000 mg). It is shown that the use of the drug Galvus Met is economically acceptable alternative to the classic scheme glimepiride + metformin in terms of intensification of treatment in patients with type 2 diabetes mellitus.
Pharmateca. 2013;(5):52-57
52-57
SAKhARNYY DIABET 2 TIPA I NEALKOGOL'NAYa ZhIROVAYa BOLEZN' PEChENI: PRAKTIChESKIE REKOMENDATsII DLYa ENDOKRINOLOGOV
Abstract
In clinical practice, type 2 diabetes mellitus (DM2) is often associated with non-alcoholic fatty liver disease (NAFLD), which includes several morphological forms and develops in patients without alcohol abuse. The combination of DM2 and NAFLD is associated not only with a high risk of liver cirrhosis and hepatocellular carcinoma in these patients. The presence of NAFLD in DM2 patients is also a predictor of high cardiovascular risk and increased mortality. Despite the findings on the progressive nature of NAFLD in DM2 patients, treatment of NAFLD in DM2 patients remains unclear.
Pharmateca. 2013;(5):58-69
58-69
AKROMEGALIYa: VAZhNOST' OTsENKI SISTEMNYKh PROYaVLENIY ZABOLEVANIYa I IKh TERAPII, ROL' ANALOGOV SOMATOSTATINA
Abstract
High mortality rate among patients with acromegaly is associated with prolonged effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess. An adequate treatment of acromegaly is to be aimed at these hormones levels reducing, system and metabolic complications treatment and pituitary tumor shrinkage. Mortality rates for this disease have significantly decreased last decades due to the development of effective treatments, particularly modern somatostatin analogues. This group includes the lanreotide Autogel - an effective drug for the treatment of acromegaly which reduces GH and IGF-1 levels and clinical symptoms of the disease.
Pharmateca. 2013;(5):70-75
70-75
PERSPEKTIVNYE STRATEGII V LEChENII DIABETIChESKOY POLINEVROPATII: ROL' ANTIOKSIDANTNOY TERAPII
Abstract
This article describes the pathogenesis of diabetic polyneuropathy. Special attention is paid to oxidative stress as a primary mechanism leading to damage to the nervous tissue. The modern views on the potentials of pathogenetic antioxidant therapy for preventing the irreversible destruction of the nerve fibers, progression of diabetic neuropathy and long-lasting maintaining of effect achieved are presented.
Pharmateca. 2013;(5):76-80
76-80
PREIMUShchESTVA METFORMINA PROLONGIROVANNOGO DEYSTVIYa
Abstract
The article presents data on the properties and effects of metformin - antihyperglycemic drug for first-line treatment of type 2 diabetes mellitus. So far, the use of metformin was limited to the development of side effects from the gastrointestinal tract and the large number of intakes of required dose of the drug, but introduction of long-acting form of metformin, Glucophage Long, allows to resolve the this problem.
Pharmateca. 2013;(5):81-85
81-85
KLINIChESKIE PREIMUShchESTVA PERVOGO ANALOGA ChELOVEChESKOGO GPP-1 LIRAGLUTIDA PRI LEChENII BOL'NYKh SAKhARNYM DIABETOM 2 TIPA
Abstract
Hypoglycemic agents, the mechanism of action of which is based on the effects of incretins, represent totally new and unique class of drugs providing pathogenetically relevant complex therapeutic approach to the treatment of patients with type 2 diabetes mellitus. Currently, results of completed clinical studies and experience in application in clinical practice have shown convincingly that liraglutide ( Victoza®) is the most effective and safe drug for the achievement of goals of therapy in patients with type 2 diabetes mellitus at early stages of treatment. The potentials for the effective and permanent weight loss when using liraglutide is an important argument in favor of its administration during choice of therapy in DM2 patients with overweight or obesity.
Pharmateca. 2013;(5):86-91
86-91
AMIODARON I DISFUNKTsIYa ShchITOVIDNOY ZhELEZY
Abstract
One of the main anti-arrhythmic drugs used in the treatment of patients with atrial fibrillation, is amiodarone. However, amiodarone can cause thyroid dysfunction, and the question of its cancellation or continuation of treatment should be decided individually for each patient. Clinical experience has shown that the choice can be made in favor of the continuation of treatment with original drug in most cases. Development of amiodarone-associated hypothyroidism and euthyroid hyperthyroxinemia is not accompanied by a loss of antiar-rhythmic activity of drug, and its compensation by L-thyroxine is not accompanied by reinitiation of rhythm disturbances. Development of amiodarone-associated hyperthyroidism is associated with loss of antiarrhythmic activity of drug, and its correction - with the restoration of this effect.
Pharmateca. 2013;(5):92-96
92-96
BIOSIMILYaRY: PROBLEMY ZAMEShchENIYa I SOVREMENNYE TREBOVANIYa K VOSPROIZVEDENNYM PREPARATAM INSULINA
Abstract
To date, numerous studies have convincingly proved significant differences in the efficacy and safety of treatment between the original and generic biotechnological drugs (biosimilars). However, despite abundant evidence of therapeutic inequivalence, there is a problem of “automatic" replacement of original drugs on biosimilars due to lower cost. This situation calls for the revision of the legal framework governing the circulation of biosimilars our country.
Pharmateca. 2013;(5):97-103
97-103